Data from a 10-year follow-up study showed declining kidney function is significantly associated with dementia risk among older adults.
Results of a 10-year follow up of a cohort study revealed poor and declining kidney function in older adults is associated with a higher risk of dementia. Findings, published in Age and Aging, also showed the association is not attributable to stroke and persists after accounting for major cardiometabolic conditions, authors wrote.
Previous research has indicated cognitive impairment is common among patients with end-stage renal disease undergoing hemodialysis, while a graded association exists between chronic kidney disease (CKD) severity and cognitive impairment.
“The kidneys and the brain, both being end organs, are thought to be susceptible to vascular damage due to similar anatomic and hemodynamic features,” the researchers explained, proposing one possible common underlying mechanism.
Globally, CKD prevalence is increasing due in part to increasing rates of hypertension, diabetes, and obesity.
To better elucidate the relationship between estimated glomerular filtration rate (eGFR) and dementia, the investigators assessed data that were compiled for over 10 years in a large community dwelling as part of the Whitehall II cohort study. This study was established in 1985 and originally included data on 10,308 individuals. Since the study’s inception, follow-up clinical examinations have taken place every 4 to 5 years, while in the current analysis, baseline data on kidney function measured between 2007 and 2009 were utilized.
Data were also linked with electronic health records of the United Kingdom National Health Service and all-cause dementia was identified based on International Classification of Diseases, 10th Revision codes. Individuals were followed until the recorded date of dementia, death, or March 31, 2019.
Changes in eGFR were measured at follow-up appointments that took place between 2012 and 2013. A total of 6050 adults with a mean age of 65.8 (5.9) years were included in the current analysis.
The researchers found:
Mean (SD) age at dementia diagnosis was 78.1 (5.3) years and these individuals tended to have worse sociodemographic and health profiles at baseline.
Overall, the researchers noted 3 key findings:
Current results are in accordance with previously published research, but the exact underlying mechanisms linking the 2 conditions remain unclear.
In the Whitehall II analysis, the researchers were only able to adjust for traditional risk factors, marking a limitation to the study. Participants included were also more likely to be healthier than those with advanced kidney disease, while the follow-up period employed “is not long enough to rule out reverse causations where estimates can be biased due to the long preclinical phase of dementia affecting multiple processes,” the authors wrote.
Cost of care, increasing rates of CKD prevalence, and poor outcomes warrant the prioritization of CKD surveillance from a public health standpoint, the researchers concluded. “While cardiovascular disease and reduction in life expectancy are recognized adverse outcomes of CKD, it is possible that dementia is also part of the risk associated with CKD.”
Reference
Singh-Manoux A, Oumarou-Ibrahim A, Machado-Fragua MD, et al. Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. Age Aging. Published online January 17, 2022. doi:10.1093/ageing/afab259
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More